Cover Kidney News
Volume/Issue:
Volume 12: Issue 6
Page:
15–16
Publication Date:
01 Jun 2020
Online Publication Date:
28 May 2020
  • 1.

    Wang A, et al. Evaluation of kidney function before and after percutaneous mitral valve repair. Circ Cardiovasc Interv 2015; 8:e001349.

  • 2.

    Feldman T, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364:1395–1406.

  • 3.

    Whitlow PL, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: The EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol 2012; 59:130–139.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Estévez-Loureiro R, et al. Effect of advanced chronic kidney disease in clinical and echocardiographic outcomes of patients treated with MitraClip system. Int J Cardiol 2015; 198:75–80.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Ohno Y, et al. Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system: Insights from the GRASP registry. EuroIntervention 2016; 11:e1649–e1657.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Kaneko H, et al. Interaction between kidney function and percutaneous edge-to-edge mitral valve repair using MitraClip. J Cardiol 2017; 69:476–482.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Shah B, et al. Outcomes after transcatheter mitral valve repair in patients with kidney disease. Circ Cardiovasc Interv 2019; 12:e007552.

  • 8.

    Enriquez-Sarano M, et al. Mitral regurgitation. Lancet 2009; 373:1382–1394.

  • 9.

    Samad Z, et al. Prevalence and outcomes of left‐sided valvular heart disease associated with chronic kidney disease. J Am Heart Assoc 2017; 6:e006044.

    • Crossref
    • Search Google Scholar
    • Export Citation
Editorial Type:
Special Section

TRANSCATHETER MITRAL VALVE REPAIR (MitraClip) and the Kidney

Mohammed Elsadany1, Yifeng Yang1, Sonali Gupta1, and Joseph Mattana1
  • 1 Mohammed Elsadany, MD, Yifeng Yang, MD, and Joseph Mattana, MD, are associated with St. Vincent’s Medical Center, Bridgeport, Connecticut, and the Quinnipiac University Frank H. Netter MD School of Medicine, North Haven, Connecticut. Sonali Gupta, MD, is associated with the University of Rochester, Rochester, New York.
Volume/Issue:
Volume 12: Issue 6
Publication Date:
01 Jun 2020
Page:
15–16
Restricted access

Transcatheter mitral valve repair (TMVR) is a minimally invasive procedure used as a treatment option for patients with symptomatic chronic moderate to severe, or severe mitral regurgitation (MR). The MitraClip is an edge-to-edge leaflet repair device and is currently the only device approved by the U.S. Food and Drug Administration for TMVR. MR is one of the most common valve lesions. Patients with chronic kidney disease (CKD) and MR usually have multiple comorbidities, increasing their surgical risk for valve replacement and making them possible candidates for TMVR by use of the MitraClip. The interaction between MR and the kidney is
Save